MedPath

ON RANDAMISED CLINICAL STUDY OF SIDDHA MEDICINE PERUNGAYA CHOORANAM FOR ACID REFLUX DISEASE

Phase 2
Conditions
Health Condition 1: K210- Gastro-esophageal reflux disease with esophagitis
Registration Number
CTRI/2022/11/047439
Lead Sponsor
MAGUDAPATHI S
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1 Age 18 -60 all gender

2 Epigastric burning

3 Sign of acid reflux

4 Indigestion

5 Abdominal pain

6 Nausea

7 Abdominal bloating

8 H/o NSAID administration

9 FSSG SCALE FOR GERD SCORE

Exclusion Criteria

1 Pregnancy & lactation

2 CA of stomach

3 Barrett esophagus

4 acute pancreatitis

5 Cholelithiasis

6 Pyloric stenosis

7 Gastric perforation

8 H/o Corticosteroid drug

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Reduction of epigastric burning vomiting nausea cough dysphagia abdominal bloating Any one or more of the above results will be considered as primary outcome over the course of 3 or 4 weeks using FSSG GERD SCALETimepoint: The primary outcome will be assessed after a period of 48 days
Secondary Outcome Measures
NameTimeMethod
The safety and efficacy of the drug will be assessed during the course of the studyTimepoint: The safety and efficacy will be assessed in a time period of 48 days
© Copyright 2025. All Rights Reserved by MedPath